Prefrontal cortical GABA abnormalities are associated with reduced hippocampal volume in major depressive disorder

European Neuropsychopharmacology

Volumn 25, Issue 8, 2015, Pages 1082-1090

  Abdallah, Chadi G ^a,b   Jackowski, Andrea ^c   Sato, João R ^c,d   Mao, Xiangling ^e   Kang, Guoxin ^e   Cheema, Raminder ^a,b   Coplan, Jeremy D ^f   Mathew, Sanjay J ^g,h   Shungu, Dikoma C ^e  

^a National Center for PTSD   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^d UNIVERSIDADE FEDERAL DO ABC   (Brazil)

^e WEILL CORNELL MEDICAL COLLEGE   (United States)

^f Downstate Health Sciences University   (United States)

^g MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

^h BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Hippocampal volume; Magnetic resonance spectroscopy (1H MRS); Major depressive disorder (MDD); MRI; Treatment resistant depression; Aminobutyric acid (GABA)

Indexed keywords

4 AMINOBUTYRIC ACID;

ADULT; ANTERIOR CINGULATE; ARTICLE; BRAIN DISEASE; BRAIN SIZE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HIPPOCAMPUS; HUMAN; MAJOR DEPRESSION; MALE; NEUROTRANSMISSION; NUCLEAR MAGNETIC RESONANCE IMAGING; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; TREATMENT RESISTANT DEPRESSION; CINGULATE GYRUS; METABOLISM; ORGAN SIZE; PATHOLOGY;

ADULT; DEPRESSIVE DISORDER, MAJOR; FEMALE; GAMMA-AMINOBUTYRIC ACID; GYRUS CINGULI; HIPPOCAMPUS; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; ORGAN SIZE; PREFRONTAL CORTEX; PROTON MAGNETIC RESONANCE SPECTROSCOPY;

EID: 84938750313     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2015.04.025     Document Type: Article

References (50)

1. Abdallah C.G., Coplan J.D., Jackowski A., Sato J.R., Mao X., Shungu D.C., Mathew S.J. A pilot study of hippocampal volume and N-acetylaspartate (NAA) as response biomarkers in riluzole-treated patients with GAD. Eur. Neuropsychopharmacol. 2013, 23:276-284.
2. Abdallah C.G., Salas R., Jackowski A., Baldwin P., Sato J.R., Mathew S.J. Hippocampal volume and the rapid antidepressant effect of ketamine. J. Psychopharmacol. 2014.
3. Auer D.P., Putz B., Kraft E., Lipinski B., Schill J., Holsboer F. Reduced glutamate in the anterior cingulate cortex in depression: an in vivo proton magnetic resonance spectroscopy study. Biol. Psychiatry 2000, 47:305-313.
4. Banasr M., Chowdhury G.M., Terwilliger R., Newton S.S., Duman R.S., Behar K.L., Sanacora G. Glial pathology in an animal model of depression: reversal of stress-induced cellular, metabolic and behavioral deficits by the glutamate-modulating drug riluzole. Mol. Psychiatry 2010, 15:501-511.
5. Bhagwagar Z., Wylezinska M., Jezzard P., Evans J., Boorman E., P, M.M., P, J.C. Low GABA concentrations in occipital cortex and anterior cingulate cortex in medication-free, recovered depressed patients. Int. J. Neuropsychopharmacol. 2008, 11:255-260.
6. 13C]-nuclear magnetic resonance spectroscopy measures of ketamine's effect on amino acid neurotransmitter metabolism. Biol. Psychiatry 2012, 71:1022-1025.
7. Collins P.Y., Patel V., Joestl S.S., March D., Insel T.R., Daar A.S., Anderson W., Dhansay M.A., Phillips A., Shurin S., Walport M., Ewart W., Savill S.J., Bordin I.A., Costello E.J., Durkin M., Fairburn C., Glass R.I., Hall W., Huang Y., Hyman S.E., Jamison K., Kaaya S., Kapur S., Kleinman A., Ogunniyi A., Otero-Ojeda A., Poo M.M., Ravindranath V., Sahakian B.J., Saxena S., Singer P.A., Stein D.J. Grand challenges in global mental health. Nature 2011, 475:27-30.
8. de Diego-Adelino J., Portella M.J., Gomez-Anson B., Lopez-Moruelo O., Serra-Blasco M., Vives Y., Puigdemont D., Perez-Egea R., Alvarez E., Perez V. Hippocampal abnormalities of glutamate/glutamine, N-acetylaspartate and choline in patients with depression are related to past illness burden. J. Psychiatry Neurosci.: JPN 2013, 38:107-116.
9. Drevets W.C., Price J.L., Furey M.L. Brain structural and functional abnormalities in mood disorders: implications for neurocircuitry models of depression. Brain Struct. Funct. 2008, 213:93-118.
10. First M., Spitzer R., Gibbon M., Williams J. Structured Clinical Interview for DSM-IV Axis I Disorders: Patient Edition (SCIDI/P. Version 2.0 1995, Biometric Research, New York State Psychiatric Institute, New York.
11. Fischl B., Salat D.H., Busa E., Albert M., Dieterich M., Haselgrove C., van der Kouwe A., Killiany R., Kennedy D., Klaveness S., Montillo A., Makris N., Rosen B., Dale A.M. Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain. Neuron 2002, 33:341-355.
12. Frodl T., Jager M., Smajstrlova I., Born C., Bottlender R., Palladino T., Reiser M., Moller H.J., Meisenzahl E.M. Effect of hippocampal and amygdala volumes on clinical outcomes in major depression: a 3-year prospective magnetic resonance imaging study. J. Psychiatry Neurosci. 2008, 33:423-430.
13. Frodl T., Meisenzahl E.M., Zetzsche T., Hohne T., Banac S., Schorr C., Jager M., Leinsinger G., Bottlender R., Reiser M., Moller H.J. Hippocampal and amygdala changes in patients with major depressive disorder and healthy controls during a 1-year follow-up. J. Clin. Psychiatry 2004, 65:492-499.
14. Gabbay V., Mao X., Klein R.G., Ely B.A., Babb J.S., Panzer A.M., Alonso C.M., Shungu D.C. Anterior cingulate cortex gamma-aminobutyric acid in depressed adolescents: relationship to anhedonia. Arch. Gen. Psychiatry 2012, 69:139-149.
15. Gorman J.M., Docherty J.P. A hypothesized role for dendritic remodeling in the etiology of mood and anxiety disorders. J. Neuropsychiatry Clin. Neurosci. 2010, 22:256-264.
16. Grimm S., Luborzewski A., Schubert F., Merkl A., Kronenberg G., Colla M., Heuser I., Bajbouj M. Region-specific glutamate changes in patients with unipolar depression. J. Psychiatr Res. 2012, 46:1059-1065.
17. Hasler G., Northoff G. Discovering imaging endophenotypes for major depression. Mol. Psychiatry 2011, 16:604-619.
18. Hasler G., van der Veen J.W., Tumonis T., Meyers N., Shen J., Drevets W.C. Reduced prefrontal glutamate/glutamine and gamma-aminobutyric acid levels in major depression determined using proton magnetic resonance spectroscopy. Arch. Gen. Psychiatry 2007, 64:193-200.
19. Horn D.I., Yu C., Steiner J., Buchmann J., Kaufmann J., Osoba A., Eckert U., Zierhut K.C., Schiltz K., He H., Biswal B., Bogerts B., Walter M. Glutamatergic and resting-state functional connectivity correlates of severity in major depression-the role of pregenual anterior cingulate cortex and anterior insula. Front. Syst. Neurosci. 2010, 4.
20. Hsieh M.H., McQuoid D.R., Levy R.M., Payne M.E., MacFall J.R., Steffens D.C. Hippocampal volume and antidepressant response in geriatric depression. Int. J. Geriatr. Psychiatry 2002, 17:519-525.
21. Insel T.R., Sahakian B.J., Voon V., Nye J., Brown V.J., Altevogt B.M., Bullmore T., Goodwin G.M., Howard R.J., Kupfer D.J. Drug research: a plan for mental illness. Nature 2012, 483.
22. Kapur S., Phillips A.G., Insel T.R. Why has it taken so long for biological psychiatry to develop clinical tests and what to do about it?. Mol. Psychiatry 2012, 17:1174-1179.
23. Kassem M.S., Lagopoulos J., Stait-Gardner T., Price W.S., Chohan T.W., Arnold J.C., Hatton S.N., Bennett M.R. Stress-induced grey matter loss determined by MRI is primarily due to loss of dendrites and their synapses. Mol. Neurobiol. 2013, 47:645-661.
24. Kronmuller K.T., Pantel J., Kohler S., Victor D., Giesel F., Magnotta V.A., Mundt C., Essig M., Schroder J. Hippocampal volume and 2-year outcome in depression. Br. J. Psychiatry 2008, 192:472-473.
25. Levinson A.J., Fitzgerald P.B., Favalli G., Blumberger D.M., Daigle M., Daskalakis Z.J. Evidence of cortical inhibitory deficits in major depressive disorder. Biol. Psychiatry 2010, 67:458-464.
26. Li N., Liu R.J., Dwyer J.M., Banasr M., Lee B., Son H., Li X.Y., Aghajanian G., Duman R.S. Glutamate N-methyl-d-aspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure. Biol. Psychiatry 2011, 69:754-761.
27. MacQueen G., Frodl T. The hippocampus in major depression: evidence for the convergence of the bench and bedside in psychiatric research?. Mol. Psychiatry 2011, 16:252-264.
28. MacQueen G.M., Yucel K., Taylor V.H., Macdonald K., Joffe R. Posterior hippocampal volumes are associated with remission rates in patients with major depressive disorder. Biol. Psychiatry 2008, 64:880-883.
29. McKinnon M.C., Yucel K., Nazarov A., MacQueen G.M. A meta-analysis examining clinical predictors of hippocampal volume in patients with major depressive disorder. J. Psychiatry Neurosci. 2009, 34:41-54.
30. Merkl A., Schubert F., Quante A., Luborzewski A., Brakemeier E.L., Grimm S., Heuser I., Bajbouj M. Abnormal cingulate and prefrontal cortical neurochemistry in major depression after electroconvulsive therapy. Biol. Psychiatry 2011, 69:772-779.
31. Morey R.A., Petty C.M., Xu Y., Hayes J.P., Wagner H.R., Lewis D.V., LaBar K.S., Styner M., McCarthy G. A comparison of automated segmentation and manual tracing for quantifying hippocampal and amygdala volumes. NeuroImage 2009, 45:855-866.
32. Petty F., Kramer G.L., Gullion C.M., Rush A.J. Low plasma gamma-aminobutyric acid levels in male patients with depression. Biol. Psychiatry 1992, 32:354-363.
33. Pfleiderer B., Michael N., Erfurth A., Ohrmann P., Hohmann U., Wolgast M., Fiebich M., Arolt V., Heindel W. Effective electroconvulsive therapy reverses glutamate/glutamine deficit in the left anterior cingulum of unipolar depressed patients. Psychiatry Res. 2003, 122:185-192.
34. Portella M.J., de Diego-Adelino J., Gomez-Anson B., Morgan-Ferrando R., Vives Y., Puigdemont D., Perez-Egea R., Ruscalleda J., Enric A., Perez V. Ventromedial prefrontal spectroscopic abnormalities over the course of depression: a comparison among first episode, remitted recurrent and chronic patients. J. Psychiatr. Res. 2011, 45:427-434.
35. Price R.B., Shungu D.C., Mao X., Nestadt P., Kelly C., Collins K.A., Murrough J.W., Charney D.S., Mathew S.J. Amino acid neurotransmitters assessed by proton magnetic resonance spectroscopy: relationship to treatment resistance in major depressive disorder. Biol. Psychiatry 2009, 65:792-800.
36. Rosenberg D.R., Macmaster F.P., Mirza Y., Smith J.M., Easter P.C., Banerjee S.P., Bhandari R., Boyd C., Lynch M., Rose M., Ivey J., Villafuerte R.A., Moore G.J., Renshaw P. Reduced anterior cingulate glutamate in pediatric major depression: a magnetic resonance spectroscopy study. Biol. Psychiatry 2005, 58:700-704.
37. Rothman D.L., De Feyter H.M., de Graaf R.A., Mason G.F., Behar K.L. 13C MRS studies of neuroenergetics and neurotransmitter cycling in humans. NMR Biomed. 2011, 24:943-957.
38. Roy A., Dejong J., Ferraro T. CSF GABA in depressed patients and normal controls. Psychol. Med. 1991, 21:613-618.
39. Sackeim H.A. The definition and meaning of treatment-resistant depression. J. Clin. Psychiatry 2001, 62(16):10-17.
40. Sanacora G., Banasr M. From pathophysiology to novel antidepressant drugs: glial contributions to the pathology and treatment of mood disorders. Biol. Psychiatry 2013, 73:1172-1179.
41. Sanacora G., Gueorguieva R., Epperson C.N., Wu Y.T., Appel M., Rothman D.L., Krystal J.H., Mason G.F. Subtype-specific alterations of gamma-aminobutyric acid and glutamate in patients with major depression. Arch. Gen. Psychiatry 2004, 61:705-713.
42. Sanacora G., Treccani G., Popoli M. Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders. Neuropharmacology 2012, 62:63-77.
43. Sheline Y.I., Disabato B.M., Hranilovich J., Morris C., D'Angelo G., Pieper C., Toffanin T., Taylor W.D., MacFall J.R., Wilkins C., Barch D.M., Welsh-Bohmer K.A., Steffens D.C., Krishnan R.R., Doraiswamy P.M. Treatment course with antidepressant therapy in late-life depression. Am. J. Psychiatry 2012, 169:1185-1193.
44. Trivedi M.H., Rush A.J., Wisniewski S.R., Nierenberg A.A., Warden D., Ritz L., Norquist G., Howland R.H., Lebowitz B., McGrath P.J., Shores-Wilson K., Biggs M.M., Balasubramani G.K., Fava M. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am. J. Psychiatry 2006, 163:28-40.
45. Vakili K., Pillay S.S., Lafer B., Fava M., Renshaw P.F., Bonello-Cintron C.M., Yurgelun-Todd D.A. Hippocampal volume in primary unipolar major depression: a magnetic resonance imaging study. Biol. Psychiatry 2000, 47:1087-1090.
46. Walter M., Henning A., Grimm S., Schulte R.F., Beck J., Dydak U., Schnepf B., Boeker H., Boesiger P., Northoff G. The relationship between aberrant neuronal activation in the pregenual anterior cingulate, altered glutamatergic metabolism, and anhedonia in major depression. Arch. Gen. Psychiatry 2009, 66:478-486.
47. Yang S., Hu J., Kou Z., Yang Y. Spectral simplification for resolved glutamate and glutamine measurement using a standard STEAM sequence with optimized timing parameters at 3, 4, 4.7, 7, and 9.4T. Magn. Reson. Med. 2008, 59:236-244.
48. Yuen E.Y., Wei J., Liu W., Zhong P., Li X., Yan Z. Repeated stress causes cognitive impairment by suppressing glutamate receptor expression and function in prefrontal cortex. Neuron 2012, 73:962-977.
49. Zhang C., Li Z., Wu Z., Chen J., Wang Z., Peng D., Hong W., Yuan C., Wang Z., Yu S., Xu Y., Xu L., Xiao Z., Fang Y. A study of N-methyl-d-aspartate receptor gene (GRIN2B) variants as predictors of treatment-resistant major depression. Psychopharmacology 2013, (Berl).
50. Zhang J., Narr K.L., Woods R.P., Phillips O.R., Alger J.R., Espinoza R.T. Glutamate normalization with ECT treatment response in major depression. Mol. Psychiatry 2013, 18:268-270.